- |||||||||| Review, Journal: Maternal Substance Use and Early-Life Adversity: Inducing Drug Dependence in Offspring, Interactions, Mechanisms, and Treatments. (Pubmed Central) - Apr 23, 2024
Treatments include antidepressants, histone deacetylase inhibitors, lamotrigine, ketamine, choline, modafinil, methadone, dopamine, cannabinoid 1 receptor agonists/antagonists, vitamins, oxytocin, tetrahydrocannabinol, SR141716A, and dronabinol. Finally, the study emphasizes the need for multifaceted strategies to prevent these outcomes.
- |||||||||| dronabinol oral / Generic mfg.
Trial completion, Trial completion date: Dronabinol in Total Knee Arthroplasty (TKA) (clinicaltrials.gov) - Apr 7, 2024
P4, N=114, Completed,
Finally, the study emphasizes the need for multifaceted strategies to prevent these outcomes. Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Apr 2024
- |||||||||| dronabinol oral / Generic mfg.
Journal, HEOR: Effects of Dronabinol on Dyspnea and Quality of Life in Patients with COPD. (Pubmed Central) - Feb 4, 2024
There were no significant differences in fatigue at rest and post-exercise, SGRQ scores or GDS scores. In this pilot study, dronabinol did not significantly improve dyspnea or exercise capacity compared with placebo.
- |||||||||| dronabinol oral / Generic mfg.
Enrollment open, Trial completion date: PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults (clinicaltrials.gov) - Jan 23, 2024
P1, N=30, Recruiting,
Trial completion date: May 2022 --> May 2025 | Trial primary completion date: Apr 2022 --> Apr 2025 Not yet recruiting --> Recruiting | Trial completion date: Jul 2025 --> Apr 2025
- |||||||||| Sativex (nabiximols) / Jazz
Enrollment closed, Enrollment change: Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain (clinicaltrials.gov) - Dec 29, 2023
P2, N=21, Active, not recruiting,
However, attention could be paid to cannabinoid doses associated with opioid reduction in included observational studies. Recruiting --> Active, not recruiting | N=320 --> 21
- |||||||||| dronabinol oral / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: DOPE: Dronabinol On the Pain Experience (clinicaltrials.gov) - Dec 13, 2023
P4, N=664, Recruiting,
There appears to be evidence to necessitate further high quality RCTs into novel formulations of phytocannabinoids for the treatment of NP. Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Nov 2023 --> Apr 2024
- |||||||||| betahistine intranasal (AM-201) / Altamira Therap
Preclinical, Journal: Effects of cannabinoid agonists and antagonists in male rats discriminating the synthetic cannabinoid AM2201. (Pubmed Central) - Dec 11, 2023
Next, the generalization profiles of AM411 and AM4089 with CB full agonists (JWH-018, CP-55,940, AM8936), partial agonist (?-THC), and non-cannabinoids (fentanyl, atropine) were compared...All CB drugs were more potent than ?-THC and correlation analysis confirmed that the relative behavioral potencies of CBs corresponded strongly with their relative affinities at the CB but not CB receptors. Together, our results further demonstrate that AM411 and AM4089 exhibit better pharmacological profiles compared to ?-THC, in that they are more potent and display in vivo partial agonist-like actions that are centrally mediated via CB receptors.
- |||||||||| dronabinol oral / Generic mfg.
Trial completion date, Trial initiation date: SAGE: Age-dependent Effects of Smoked and Oral Delta-9-THC (clinicaltrials.gov) - Nov 29, 2023
P1, N=103, Not yet recruiting,
Clinical trial information: NCT03984214. Trial completion date: Aug 2028 --> Mar 2029 | Initiation date: Aug 2023 --> Mar 2024
- |||||||||| dronabinol oral / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults (clinicaltrials.gov) - Nov 18, 2023
P1, N=50, Recruiting,
Trial completion date: Aug 2028 --> Mar 2029 | Initiation date: Aug 2023 --> Mar 2024 Completed --> Recruiting | Trial completion date: Dec 2022 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Jun 2024
- |||||||||| dronabinol oral / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Investigating the Effect of Dronabinol on Post-surgical Pain (clinicaltrials.gov) - Nov 13, 2023
P1, N=0, Withdrawn,
Completed --> Recruiting | Trial completion date: Dec 2022 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Jun 2024 N=80 --> 0 | Trial completion date: Aug 2050 --> Aug 2027 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2050 --> Aug 2027
- |||||||||| dronabinol oral / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: THC-ETOH-III: Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III (clinicaltrials.gov) - Nov 1, 2023
P1, N=40, Active, not recruiting,
N=80 --> 0 | Trial completion date: Aug 2050 --> Aug 2027 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2050 --> Aug 2027 Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| dronabinol oral / Generic mfg.
Enrollment closed, Trial primary completion date: Dronabinol in Total Knee Arthroplasty (TKA) (clinicaltrials.gov) - Oct 30, 2023
P4, N=114, Active, not recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2024 --> Oct 2023
- |||||||||| ondansetron / Generic mfg., dronabinol oral / Generic mfg.
Payor-driven denials and delays for cancer-related supportive care medications. (4th Floor, Grand Ballroom, Salon F) - Oct 13, 2023 - Abstract #ASCOQC2023ASCO_QC_54;
PA can have a negative impact on the medication management of cancer-related pain and nausea: over one-half of supportive care medications had a ?1 day delay, and 8% were denied altogether. Denials, or even brief delays, of provider-prescribed medication to ease symptom burden may lead to downstream increases in patient morbidity and payor costs, including symptom-related emergency room visits and hospitalization.
- |||||||||| dronabinol oral / Generic mfg.
Enrollment change: PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults (clinicaltrials.gov) - Oct 5, 2023
P1, N=30, Not yet recruiting,
Denials, or even brief delays, of provider-prescribed medication to ease symptom burden may lead to downstream increases in patient morbidity and payor costs, including symptom-related emergency room visits and hospitalization. N=20 --> 30
- |||||||||| dronabinol oral / Generic mfg.
Neurobiological Mechanisms of Anxiety and Anorexia Nervosa: Indications for Novel Psychopharmacological Treatments (Bryant Suite (New York Hilton Midtown); In-person) - Sep 30, 2023 - Abstract #AACAP2023AACAP_44;
Results A double-blind placebo-controlled crossover showed that tetrahydrocannabinol dronabinol produced weight gain in women with severe relapsing AN...Conclusions Further research on these novel psychopharmacological interventions is warranted. However, the available pilot data show promising clinically actionable results regarding the identification, course, treatment, and outcomes in youth with AN and ANX.
- |||||||||| cisplatin / Generic mfg.
Preclinical, Journal: Deciphering key genes involved in cisplatin resistance in kidney renal clear cell carcinoma through a combined in silico and in vitro approach. (Pubmed Central) - Sep 25, 2023
Thus, hub genes can be targeted with Alvocidib, Estradiol, Tretinoin, Capsaicin, Dronabinol, Metribolone, Calcitriol, Acetaminophen, Acitretin, Cyclosporine, Azacitidine, Genistein, and Resveratrol drugs. As the pathogenesis of KIRC is complex, targeting hub genes and associated pathways involved in cisplatin resistance could bring a milestone change in the drug discovery and management of drug resistance, which might uplift overall survival among KIRC patients.
- |||||||||| bortezomib / Generic mfg.
PERIPHERAL AND SEVERE AUTONOMIC NEUROPATHY CHARACTERIZED BY DIZZINESS, ORTHOSTATIC HYPOTENSION AND WEIGHT LOSS CAUSED BY BORTEZOMIB. (Trianti Upper Foyer; In Person) - Sep 10, 2023 - Abstract #IMW2023IMW_752;
Severe AN characterized by weight loss, dizziness, OH in association with painful neuropathy is an under recognized complication of B. Transplantation without resolution of symptoms could possibly worsen the morbidity and delay post-transplant recovery. To the best of our knowledge, we are the first group to report a series of patients with this symptom complex and strongly feel it should be studied further in a larger cohort of patients.
- |||||||||| dronabinol oral / Generic mfg., methadone / Generic mfg.
Journal: Delta-9-tetrahydrocannabinol (Pubmed Central) - Sep 3, 2023
There was no indication of any interaction between THC and methadone doses. Collectively, these results provide valuable insights for future studies aiming to evaluate the risk-benefit profile of cannabinoids to relieve pain among individuals receiving opioid agonist therapy for OUD, a timely endeavour amidst the opioid crisis.
- |||||||||| dronabinol oral / Generic mfg.
Trial completion date, Trial primary completion date: Dronabinol in Total Knee Arthroplasty (TKA) (clinicaltrials.gov) - Aug 1, 2023
P4, N=110, Recruiting,
These findings add to the scarce literature on THC and alcohol associated changes in endocannabinoid levels and provide insights to future investigations on the roles of OEA and SEA on physiology and behaviors following THC and alcohol co-exposure during adolescence. Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Jun 2023 --> Jul 2024
- |||||||||| dronabinol oral / Generic mfg.
Journal: Characterization of Some "Hashish" Samples in the Egyptian Illicit Trafficking Market Using a Thermal Separation Probe and Gas Chromatography-Mass Spectrometry. (Pubmed Central) - Jul 24, 2023
These are cannabiorcochromene (CBC-C1), tetrahydrocannabivarin (THCV), delta-8-tetrahydrocannabinol (delta-8-THC), exo-THC, cannabichromene, cannabidiol (CBD), cannabielsoin (CBE), dronabinol (delta-9-THC), cannabigerol (CBG), and cannabinol (CBN). Phenotypic index (THC % + CBN %)/CBD %) is measured for the test samples to identify both the nature of the samples (fiber- or drug-type cannabis) and the country of origin.
- |||||||||| dronabinol oral / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults (clinicaltrials.gov) - Jul 20, 2023
P1, N=43, Completed,
Phenotypic index (THC % + CBN %)/CBD %) is measured for the test samples to identify both the nature of the samples (fiber- or drug-type cannabis) and the country of origin. Recruiting --> Completed | Trial completion date: Jun 2023 --> Dec 2022 | Trial primary completion date: Jun 2023 --> Dec 2022
- |||||||||| dronabinol oral / Generic mfg.
Trial primary completion date: PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults (clinicaltrials.gov) - Jul 12, 2023
P1, N=20, Not yet recruiting,
Recruiting --> Completed | Trial completion date: Jun 2023 --> Dec 2022 | Trial primary completion date: Jun 2023 --> Dec 2022 Trial primary completion date: Aug 2025 --> Apr 2025
- |||||||||| dronabinol oral / Generic mfg.
S19--Let's Be Blunt: Cannabis Use in CF (301 A (West); Virtual) - Jul 9, 2023 - Abstract #NACFC2023NACFC_204;
Attendees will also have the opportunity to learn about usage trends in the CF population and strategies for open and honest dialogue between the CF team and patients when it comes to the use of cannabis or CBD products.Learning Objectives: Review the differences between cannabis (THC) and cannabidiol (CBD) and available research on the benefits and risks associated with products containing these compounds. In depth review of GI specific effects of THC/CBD including appetite stimulation, use of prescription dronabinol, cyclical vomiting syndrome, and potential for CF specific absorption issues of oral/edible products.Analyze cannabis usage trends among patients with CF.Develop strategies for open dialogue and shared decision making with patients who utilize these products or are considering adding them as adjunct therapies.
- |||||||||| dronabinol oral / Generic mfg.
Trial initiation date: DOPE: Dronabinol On the Pain Experience (clinicaltrials.gov) - Jul 3, 2023
P4, N=664, Not yet recruiting,
In depth review of GI specific effects of THC/CBD including appetite stimulation, use of prescription dronabinol, cyclical vomiting syndrome, and potential for CF specific absorption issues of oral/edible products.Analyze cannabis usage trends among patients with CF.Develop strategies for open dialogue and shared decision making with patients who utilize these products or are considering adding them as adjunct therapies. Initiation date: May 2023 --> Aug 2023
- |||||||||| Journal: Evaluation of morphine, methadone, digoxin, and dronabinol poisoning during the years 2017 to 2019 in Ilam, Iran. (Pubmed Central) - May 24, 2023
In addition, there was a significant difference (P<0.01) in blood levels between men and women who used morphine. In general, it is important to understand the status of drug poisoning with drugs such as morphine, methadone, digoxin, and dronabinol, as well as the prognosis associated with the treatment process of such poisoning.
- |||||||||| dronabinol oral / Generic mfg.
Trial completion date: Tetrahydrocannabinol (THC) and Sleep (clinicaltrials.gov) - May 22, 2023
P1, N=18, Active, not recruiting,
In general, it is important to understand the status of drug poisoning with drugs such as morphine, methadone, digoxin, and dronabinol, as well as the prognosis associated with the treatment process of such poisoning. Trial completion date: Mar 2023 --> Mar 2024
- |||||||||| olanzapine / Generic mfg., mirtazapine / Generic mfg., dronabinol oral / Generic mfg.
A Review of Appetite Stimulants for Weight Restoration in Anorexia Nervosa (Hall B Foyer, Exhibition Level Moscone South) - May 17, 2023 - Abstract #APA2023APA_654;
Even more scarce has been comparative efficacy. In this poster, we aim to provide an overview of current appetite stimulant treatments for weight restoration in patients with anorexia nervosa.
- |||||||||| dronabinol oral / Generic mfg.
Trial completion date, Trial primary completion date: THC-AD: Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (clinicaltrials.gov) - May 6, 2023
P2, N=160, Recruiting,
Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Feb 2024 Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> May 2024
- |||||||||| dronabinol oral / Generic mfg.
Journal: Repositioning Cannabinoids and Terpenes as Novel EGFR-TKIs Candidates for Targeted Therapy Against Cancer: A virtual screening model using CADD and biophysical simulations. (Pubmed Central) - May 2, 2023
Nine promising phytochemicals, Cannabidiolic acid (CBDA), Cannabidiol (CBD), Tetrahydrocannabivarin (THCV), Dronabinol (?-9-THC), Delta-8-Tetrahydrocannabinol (?-8-THC), Cannabicyclol (CBL), Delta9-tetrahydrocannabinolic acid (THCA), Beta-Caryophyllene (BCP), and Gamma-Elemene (?-Ele) were identified as potential EGFR-TKIs natural product candidates for cancer therapy...This hybrid early drug discovery screening strategy has the potential to yield a new generation of EGFR-TKIs based on natural cannabis products, suitable for cancer therapy. In addition, the application of this computational strategy in the virtual screening of both natural and synthetic chemical libraries could support the discovery of a wide range of lead drug agents to address numerous diseases.
- |||||||||| dronabinol oral / Generic mfg.
Trial primary completion date: Reward and Drug Effects on Mood and Brain Response (clinicaltrials.gov) - Apr 28, 2023
P1, N=80, Recruiting,
In addition, the application of this computational strategy in the virtual screening of both natural and synthetic chemical libraries could support the discovery of a wide range of lead drug agents to address numerous diseases. Trial primary completion date: Jan 2025 --> Jun 2025
|
